Image

Asia-Pacific Melanoma Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Asia-Pacific Melanoma Cancer Diagnostics Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Dec 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 245
  • No of Figures: 39

Asia-Pacific Melanoma Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2030
Diagram Market Size (Base Year) USD MILLION
Diagram Market Size (Forecast Year) USD 1,121.28
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Asia-Pacific Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) Tests, Immunohistochemical (IHC) Tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast 2030.

Melanoma Cancer Diagnostics Market

Asia-Pacific Melanoma Cancer Diagnostics Market Analysis and Insights 

The increased demand for non-invasive testing methods globally has enhanced the market's demand. The rising healthcare expenditure for better health services is also contributing to the growth of the market. The major market players are highly focusing on various faster diagnostics during this crucial period. In addition, government initiatives for melanoma cancer diagnostics are also contributing to the rising demand for the melanoma cancer diagnostics market.

Melanoma Cancer Diagnostics Market

Melanoma Cancer Diagnostics Market

The increasing healthcare expenditure strategic initiatives by market players are giving opportunities to the market. However, the lack of skilled and certified professionals and the high cost of diagnostics procedures for melanoma cancers in emerging economies are key challenges to market growth.

The Asia-Pacific melanoma cancer diagnostics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.3% in the forecast period of 2023 to 2030 and is expected to reach USD 1,121.28 million by 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customisable to 2020-1015)

Quantitative Units

Revenue in USD Million

Segments Covered

By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales)

Countries Covered

China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, New Zealand, Vietnam, Taiwan and rest of Asia-Pacific

Market Players Covered

Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc, QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott, AMLo Biosciences Limited, Myriad genetics Genetics Inc, Castle Biosciences, DermTech, Michael Diagnostics Ltd, Damae Medical, Skin Analytics, DermLite, DermaSensor, Skyline Dx, Neracare GmbH, VERISKIN INC., Illumina Inc, and bioMerieux SA, among others

Market Definition

Melanoma cancer diagnostics are known as the process of identifying melanoma cancer by studying skin cells and molecules. These melanoma cancer diagnostics are used as a strategy to research, analyse and diagnose certain cells or molecules with the help of various tests performed in the laboratory. It is specially used for the measurement of a specific biomarker or identifying the biomarker in the skin cells. A melanoma cancer diagnosis is used with the aim of providing more efficient testing and faster diagnostics.

Melanoma cancer diagnostics help doctors find out the cancer stages to effectively treat patients at various stages. Furthermore, with the potential for clinical practice, several tests are used to give additional support to boost efficiency in melanoma cancer diagnosis, and the presence of major market players also contributes to the market growth.

Asia-Pacific Melanoma Cancer Diagnostics Market Dynamics

Drivers

  • Rising demand for early melanoma cancer diagnosis

A potentially fatal cancer, melanomas are most frequently found on the skin. The melanoma incidence has increased significantly on a Asia-Pacific scale. The incidence is highest among populations with fair skin and at lower latitudes. It is one of the cancers with the highest average number of years lost to disease per death. Melanoma is a severe personal and economic burden due to increased incidence and mortality. Various high-risk areas have employed preventative measures with varying degrees of success. The genesis of disease and risk factors must be better understood through research initiatives.

  • Rising preference for preventive health check-ups

Preventive health check-ups are preventive actions performed for the initial detection of melanoma cancer disease. Also, a rising preference for preventive health check-ups provides a safeguard against likely exposure to any disease in the future.

Awareness to promote screening is the most important component of melanoma cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.

Opportunities

  • Increasing healthcare expenditure for melanoma cancer treatment

Growing healthcare infrastructure is an opportunity for the market because if investment in healthcare increases, more people are getting aware of cancer disease and diagnose their health for precaution and cure.

Increasing healthcare expenditure for cancer treatment also helps the patient to take hassle-free advanced treatment for taking better diagnosis and treatment for fast recovery. The spending on health is made up of the combination of out-of-pocket payments (people paying for their own care), government expenditure, and sources, including health insurance and activities by non-governmental organizations. Due to this, increasing healthcare expenditure for cancer treatment is acting as an opportunity for growing the demand of the market.

  • Strategic initiatives by major players

Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. For instance, Evonik invested in the short-term growth of its specialty melanoma cancer diagnostics production at its Hanau and Dossenheim locations in Germany, which supplied two of the four melanoma cancer diagnostics for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.

Restraints/Challenges

  • Strict regulations and standards for the approval and commercialization of melanoma cancer diagnostic products

The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products globally that have their own regulations and a different body for the regulatory procedures.

Manufacturers' approval for commercializing product commercializing into the market. Due to this, in the Asia-Pacific region, stringent regulatory policies are expected to hinder the development of the cancer diagnostic market.

The regulatory requirement for approvals of marketing or CE certification and application of laws and regulations could lead to making major changes in business or paying penalties, including the potential loss of business licenses. The resources and costs required to comply with these laws, rules, and regulations are quite high. Different manufacturing challenges for lipid nanoparticle production

Post-COVID-19 Impact on the Asia-Pacific Melanoma Cancer Diagnostics Market

COVID-19 has positively affected the market. As the demand for diagnostics increased, preventive health check-ups were in high demand. Thus COVID-19 affected the melanoma cancer diagnostics market positively.

Recent Development

  • In October 2022, Quest Diagnostics Incorporated announced that the company has collaborated with Decode health to get biomarker-based data that can help reduce the time and cost of developing novel diagnostic tests and drug targets for different types of cancer. This will help the company to find innovative paths in the field of R&D and increases the Asia-Pacific presence of the company in the market
  • In May 2022, Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company's growing oncology portfolio. This results in growing liquid biopsy space for the precise tumor test

Asia-Pacific Melanoma Cancer Diagnostics Market Scope

The Asia-Pacific melanoma cancer diagnostics market is segmented into product type, test type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Instruments
  • Consumables & Accessories
  • Others

On the basis of type, the Asia-Pacific melanoma cancer diagnostics market is segmented into instruments, consumables & accessories, and others.

Test Type

  • Biopsy
  • Imaging test
  • Immunohistochemical (IHC) tests
  • Biomarkers test
  • Fluorescent In Situ Hybridization (FISH) tests
  • Comparative Genomic Hybridization (CGH) tests
  • Others

Based on test type, the Asia-Pacific melanoma cancer diagnostics market is segmented into biomarkers test, imaging test, biopsy, Fluorescent In Situ Hybridization (FISH) tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and others.

End User

  • Hospitals
  • Associated labs
  • Independent diagnostic laboratories
  • Diagnostic imaging centers
  • Cancer research institutes
  • Others

Based on end user, the Asia-Pacific melanoma cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

Based on the distribution channel, the Asia-Pacific melanoma cancer diagnostics market is segmented into direct tender, retail sales, and others.

Melanoma Cancer Diagnostics Market

Melanoma Cancer Diagnostics Market Regional Analysis/Insights    

The Asia-Pacific melanoma cancer market is analysed, and market size insights and trends are provided by product type, test type, end user, and distribution channel.

Asia-Pacific melanoma cancer market comprise of the countries the China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, New Zealand, Vietnam, Taiwan and rest of Asia-Pacific.

Australia is expected to dominate the Asia-Pacific melanoma cancer diagnostics market due to the growing demand for quality healthcare, and the rising demand for non-invasive testing methods which are expected to drive the market’s growth.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Melanoma Cancer Diagnostics Market Share Analysis

The Asia-Pacific melanoma cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the Asia-Pacific melanoma cancer diagnostics market.

Some of the major players operating in the Asia-Pacific melanoma cancer diagnostics market are Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc, QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott, AMLo Biosciences Limited, Myriad genetics Genetics Inc, Castle Biosciences, DermTech, Michael Diagnostics Ltd, Damae Medical, Skin Analytics, DermLite, DermaSensor, Skyline Dx, Neracare GmbH, VERISKIN INC., Illumina Inc, and bioMerieux SA, among others.


SKU-

TABLE 1 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC CONSUMERS & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC HOSPITALS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC ASSOCIATED LABS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 32 ASIA PACIFIC DIRECT TENDER IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC RETAIL SALES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 ASIA-PACIFIC REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 ASIA-PACIFIC PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 50 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 AUSTRALIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 52 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 AUSTRALIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 AUSTRALIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 AUSTRALIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 AUSTRALIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 57 AUSTRALIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 58 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 59 AUSTRALIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 60 AUSTRALIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 AUSTRALIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 AUSTRALIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 64 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 65 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 66 CHINA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 67 CHINA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 68 CHINA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 CHINA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 70 CHINA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 CHINA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 CHINA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 CHINA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 CHINA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 CHINA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 CHINA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 78 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 79 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 80 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 81 INDIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 INDIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 INDIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 84 INDIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 INDIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 INDIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 87 INDIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 88 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 INDIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 90 INDIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 91 INDIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 92 INDIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 93 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 94 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 95 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 96 NEW ZEALAND INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 NEW ZEALAND PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 NEW ZEALAND IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 99 NEW ZEALAND CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 100 NEW ZEALAND KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 101 NEW ZEALAND REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 NEW ZEALAND PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 NEW ZEALAND BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 NEW ZEALAND IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 NEW ZEALAND BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 NEW ZEALAND IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 109 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 110 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 111 INDONESIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 112 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 113 INDONESIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 114 INDONESIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 115 INDONESIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 116 INDONESIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 117 INDONESIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 119 INDONESIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 120 INDONESIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 INDONESIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 INDONESIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 124 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 125 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 126 JAPAN INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 127 JAPAN PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 JAPAN IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 129 JAPAN CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 130 JAPAN KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 JAPAN REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 JAPAN PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 133 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 134 JAPAN BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 135 JAPAN IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 136 JAPAN BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 137 JAPAN IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 139 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 140 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 141 THAILAND INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 142 THAILAND PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 THAILAND IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 144 THAILAND CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 145 THAILAND KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 146 THAILAND REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 147 THAILAND PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 148 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 149 THAILAND BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 THAILAND IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 151 THAILAND BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 152 THAILAND IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 153 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 154 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 155 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 156 PHILIPPINES INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 157 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 158 PHILIPPINES IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 159 PHILIPPINES CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 160 PHILIPPINES KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 161 PHILIPPINES REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 162 PHILIPPINES PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 163 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 164 PHILIPPINES BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 165 PHILIPPINES IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 166 PHILIPPINES BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 167 PHILIPPINES IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 168 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 169 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 170 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 171 VIETNAM INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 172 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 173 VIETNAM IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 174 VIETNAM CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 175 VIETNAM KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 176 VIETNAM REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 177 VIETNAM PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 178 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 179 VIETNAM BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 180 VIETNAM IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 181 VIETNAM BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 182 VIETNAM IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 183 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 184 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 185 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 186 MALAYSIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 187 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 188 MALAYSIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 189 MALAYSIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 190 MALAYSIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 191 MALAYSIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 192 MALAYSIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 193 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 194 MALAYSIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 195 MALAYSIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 196 MALAYSIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 197 MALAYSIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 198 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 199 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 200 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 201 SOUTH KOREA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 202 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 203 SOUTH KOREA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 204 SOUTH KOREA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 205 SOUTH KOREA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 206 SOUTH KOREA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 207 SOUTH KOREA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 208 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 209 SOUTH KOREA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 SOUTH KOREA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 211 SOUTH KOREA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 212 SOUTH KOREA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 213 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 214 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 215 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 216 SINGAPORE INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 218 SINGAPORE IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 219 SINGAPORE CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 220 SINGAPORE KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 221 SINGAPORE REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 222 SINGAPORE PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 223 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 SINGAPORE BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 SINGAPORE IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 226 SINGAPORE BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 227 SINGAPORE IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 228 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 229 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 230 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 231 TAIWAN INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 232 TAIWAN PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 233 TAIWAN IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 TAIWAN CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 235 TAIWAN KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 236 TAIWAN REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 237 TAIWAN PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 238 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 239 TAIWAN BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 240 TAIWAN IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 241 TAIWAN BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 242 TAIWAN IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 243 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 244 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 245 REST OF ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Asia-Pacific Melanoma Cancer Diagnostics Market is projected to grow at a CAGR of 8.3% during the forecast period by 2030.
The future market value of the Asia-Pacific Melanoma Cancer Diagnostics Market is expected to reach USD 1,121.28 million by 2030.
The major players in the Asia-Pacific Melanoma Cancer Diagnostics Market are Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc, QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott, AMLo Biosciences Limited, Myriad genetics Genetics Inc, etc.
The countries covered in the Asia-Pacific Melanoma Cancer Diagnostics Market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, New Zealand, Vietnam, Taiwan and rest of Asia-Pacific.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials